
LifeArc Ventures
Venture arm of LifeArc, UK medical research charity; participant in Cytospire's Series A.
Last refreshed: 13 May 2026 · Appears in 1 active topic
Timeline for LifeArc Ventures
Cytospire's £61m oncology Series A oversubscribed
UK Startups and InnovationWhat is LifeArc Ventures and where does its money come from?
Which UK charity backed Cytospire's cancer drug programme?
Is LifeArc connected to the MRC?
Background
LifeArc Ventures participated in Cytospire's £61m Series A in May 2026 alongside Abingworth, Servier Ventures, Sound Bioventures, and Medical Incubator Japan. Cytospire is developing CYT X300, a pan-gamma delta T cell engager targeting solid tumours; LifeArc's focus on early translational oncology and immunology makes this a strategic-fit investment.
LifeArc Ventures is the investment Arm of LifeArc, a UK not-for-profit medical research organisation. LifeArc was originally the Medical Research Council's technology transfer office; it became independent and has since commercialised assets including contributions to pembrolizumab (Keytruda), generating over £1.4bn in proceeds that fund its ongoing medical research grant programme. LifeArc Ventures deploys capital from this endowment into early-stage biotech consistent with LifeArc's translational Science mission, with a preference for UK-based or UK-academic-origin companies.